Ribbon Bio Launches Cell-Free MiroSynth DNA and New In-Lab Cell-Free DNA Production Kit
May 6, 2026
Together, these announcements represent a step forward in increasing accessibility to complex DNA
Together, these announcements represent a step forward in increasing accessibility to complex DNA
More than half a billion people worldwide are living with diabetes, the vast majority with type 2 diabetes (T2D), a chronic condition that continues to rise alongside aging populations and changing lifestyles. Despite its prevalence, the cell-type-specific mechanisms that shape beta-cell adaptation and failure over time have remained only partially understood.
A new study led by researchers from VIB and KU Leuven shows that Parkinson’s disease can be divided into distinct subtypes, helping explain why a single treatment does not work for all patients. Using a machine-learning-driven analysis, the team identified two main groups and five subgroups of the disease, marking an important step toward more personalized therapies. The findings are published in Nature Communications.
ADDISON, Texas, May 5, 2026 /PRNewswire/ — FX Shoulder Solutions, Inc. has received FDA 510(k) clearance for the FX V135® Easytech Shoulder System, the next generation of stemless shoulder arthroplasty implants that provides surgeons with an anatomic stemless versus a modular stemmed-reverse option. This design enables surgeons to begin with a stemless approach and, when clinically appropriate, transition intraoperatively to a short stem solution without changing or adding another system.
Laidlaw Scholar Nikita Bhat has studied a new way to influence metabolic signaling with greater precision
Medtronic (NYSE:MDT) announced today that it received CE mark approval for its VitalFlow Transport Frame Air and Ground (AG) accessory.
Researchers at the Champalimaud Foundation in Lisbon have for the first time managed to identify with an imaging technique whether nervous impulses in the brain of rats are flowing in a “bottom-up” (feedforward), carrying information about visual input, or a “top-down” (feedback) direction, carrying information about expectations or predictions on a given task or about the perception of the world around us.
Groundbreaking research from the University of Houston shows that a single low-dose atropine eye drop can produce daylong effects in managing myopia.
A new study published in The Journal of Prevention of Alzheimer’s Disease suggests that these oral capsules may actually be linked to a faster decline in cognitive function.
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s Faslodex but showed no such significant benefit in the intention-to-treat analysis.